Introduction {#sec1_1}
============

Primary cutaneous melanoma is an aggressive malignancy of melanocytes which accounts for only 4% of dermatologic malignancies, but is responsible for 80% of skin cancer-related deaths and, with metastatic disease, has a 5-year survival rate of only 14% \[[@B1]\]. The risk factors for melanoma are immunosuppression, ultraviolent radiation exposure, a family history of melanoma, and multiple benign or atypical nevi \[[@B2]\]. Histologically, melanomas are characterized by different growth patterns, such as superficial spreading, nodular, acral lentiginous, and lentigo maligna melanomas \[[@B3]\]. Many different melanoma driver mutations have been identified, with approximately 50--60% being mutated *BRAF* and 15--20% mutated *NRAS* Interestingly, the V600E and Q16R mutations account for roughly 90% of *BRAF* and *NRAS* mutations, respectively \[[@B4], [@B5]\]. Less common driver mutations include other *BRAF* and *NRAS* mutations as well as mutations in other genes such as *c-Kit* (2--6%), *CTNNB1* (2--3%), *GNA11* (2%), *GNAQ* (1%), and *MEK1* (2--6%) \[[@B4], [@B5], [@B6]\]. In general, melanomas with concurrent driver mutations are rare; Goel et al. \[[@B6]\] examined 69 cases of primary cutaneous melanoma and found that only 2.9% (2/69) carried concurrent *BRAF V600E* and *NRAS Q16R* mutations.

The activating *BRAF E586K* mutation, causing constitutive enzyme heterodimerization and activation, is rare in melanomas \[[@B7], [@B8]\]. Similarly, the *NRAS Q81K* mutation accounts for a small percentage of melanoma NRAS driver mutations \[[@B5]\]. Here we describe the first reported case of concurrent *BRAF E586K* and *NRAS Q16R* driver mutations in the presence of primary cutaneous melanoma.

Case Report {#sec1_2}
===========

A 42-year-old male Caucasian with a history of chronic sun exposure presented with a mole on his left shoulder that had recently become red, itchy, and inflamed. The lesion was excised and HE sections were prepared. Histologic examination revealed sheets of pleomorphic epithelial cells and a histology consistent with cutaneous melanoma (fig. [1a](#F1){ref-type="fig"}). Immunohistochemical (IHC) S100 staining showed diffuse membranous and cytoplasmic staining in most malignant cells (fig. [1b](#F1){ref-type="fig"}). Dual Mart-1 and Ki-67 IHC staining showed strong membranous Mart-1 staining (red stain) and strong Ki-67 nuclear staining (brown stain). Dual S100 and Mart-1 IHC positivity is typical of melanomas (fig. [1b, c](#F1){ref-type="fig"}) \[[@B2]\]. The nuclear Ki-67 positivity showed a brisk mitotic index of approximately 20% (fig. [1c](#F1){ref-type="fig"}). IHC staining was performed at Reliapath (Opelousas, La., USA) according to regulations of the College of American Pathologists.

Several weeks later, a PET/CT scan of the patient revealed an abnormal fluorodeoxyglucose uptake by soft tissue nodules in the anterolateral chest wall which were suggestive of metastatic disease. Additionally, the resection of a jejunal mass and 4 local lymph nodes showed a metastatic melanoma. Next-generation sequencing was done on the metastatic jejunal melanoma to analyze the tumor for possible druggable driver mutations. A sequencing analysis of the *BRAF* exons 11 and 15 and the *NRAS* exons 2 and 3 revealed concurrent *BRAF E586K* and *NRAS Q16R* driver mutations. The analysis of the *c-Kit* exons 9, 11, 13, 17, and 18 revealed no mutations.

Discussion {#sec1_3}
==========

*NRAS* mutations in melanoma commonly compromise the ability of the enzyme to hydrolyze guanosine triphosphate, allowing the enzyme to be constitutively active and activate downstream signaling proteins such as *RAS* and *BRAF* \[[@B9]\]. *RAS* and *BRAF* activities contribute to the malignant proliferation by inducing the activities of proteins including mTOR, cyclin D1, and NF-κB \[[@B9]\]. Additionally, *RAS* also activates the phosphatidylinositol 3-kinase/PTEN/Akt pathway, leading to apoptosis inhibition and malignant cell survival \[[@B9]\]. Concurrent *NRAS* and *BRAF* activating driver mutations are not expected to be common events, as they lie on the same molecular signal transduction pathway, and once one activating driver mutation occurs there would be little selective pressure for a second mutation to occur \[[@B6], [@B9]\].

To our knowledge, concurrent *BRAF E586K* and *NRAS Q81K* driver mutations have not been previously identified in melanomas. The clinical treatment of this rare combination of concurrent driver mutations in this case may be difficult, as it is unknown whether the *BRAF E586K* mutation responds to *BRAF* inhibitors. Additionally, there is in vitro evidence that *NRAS* mutations may confer resistance to *BRAF* inhibitors \[[@B5], [@B10]\].
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